Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02299570 · ClinicalTrials.gov registry record · Phase 2
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
A Phase 2 study of Enterocolitis Clostridium Difficile Recurrent, sponsored by Rebiotix.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT02299570 is a Phase 2 study of Enterocolitis Clostridium Difficile Recurrent that has completed, run by Rebiotix. The registered enrollment target is 150 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT02299570, a Phase 2 study of Enterocolitis Clostridium Difficile Recurrent, has completed, sponsored by Rebiotix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is the first prospective, multi-center, double-blinded, randomized controlled study of a microbiota suspension derived from intestinal microbes. Patients who have had at least two recurrences of C. difficile infection (CDI) after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization may be eligible for the study. Patients whose CDI returns in less than 8 weeks after the last assigned study treatment may be eligible to receive up to 2 treatments with RBX2660 in the open-label portion of the study.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL RBX2660 (microbiota suspension)
Study Locations (20)
New York
- New York Hospital Queens - Flushing
- New York-Presbyterian Hospital/Weill Cornell Medical College - New York
- Gastroenterology Group of Rochester - Rochester
Illinois
- Loyola University Chicago - Chicago
- University of Chicago - Chicago
Minnesota
- Mayo Clinic Minnesota - Rochester
- Regions Hospital - Saint Paul
Ohio
- Louis Stokes Cleveland VA Medical Center - Cleveland
- Regional Infectious Diseases and Infusion Center - Lima
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- University of Colorado - Aurora
Florida
- Borland-Groover Clinic - Jacksonville
Idaho
- Grand Teton Research Group - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02299570
The ClinicalTrials.gov registry entry for NCT02299570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rebiotix, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Enterocolitis Clostridium Difficile Recurrent appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02299570 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02299570 about?
NCT02299570 is a clinical study titled "Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection". This is the first prospective, multi-center, double-blinded, randomized controlled study of a microbiota suspension derived from intestinal microbes. Patients who have had at least two recurrences of C. difficile infection (CDI) after a primary episode and have completed at least two rounds of stand...
What is the current status of trial NCT02299570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2014-12. Estimated completion is 2018-01.
What conditions does trial NCT02299570 study?
This clinical trial studies the following conditions: Enterocolitis Clostridium Difficile Recurrent.
What interventions are being tested in trial NCT02299570?
The interventions under investigation include: Placebo (OTHER), RBX2660 (microbiota suspension) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02299570?
This trial is sponsored by Rebiotix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02299570 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.